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Abstract
Background: The Whey Acidic Protein domain is an evolutionarily conserved motif found in a number of proteins, the best
studied of which are antiproteinases involved in the innate immune defence of multiple epithelia. We recently characterised the
WFDC2 gene which encodes a two WAP domain-containing protein, initially suggested as a marker for epididymis, and showed
that it is highly expressed in the lung and salivary gland. The precise location of WFDC2 protein in these sites has not been
described.
Methods: We used immunohistochemistry to localise WFDC2 in normal tissues of the respiratory tract, naso- and oropharynx,
as well as in chronically inflamed lung from Cystic Fibrosis and a range of pulmonary carcinomas. We have complemented these
studies with molecular analysis of WFDC2 gene expression in primary human lung cell cultures.
Results: WFDC2 is expressed in some epithelial cells of the upper airways as well as in mucous cells and ducts of submucosal
glands. No staining was seen in peripheral lung. Intense staining is found in major salivary glands and in minor glands of the nose,
sinuses, posterior tongue and tonsil. Studies with the related protein Secretory Leukocyte Protease Inhibitor (SLPI) show that
although both proteins are expressed in similar tissues, the precise cellular localisation differs. Significant increases in expression
and localisation of WFDC2 are seen in patients with Cystic Fibrosis. SLPI expression was greatly reduced in the same samples.
In cultures of tracheobronchial epithelial cells, expression of WFDC2 and SLPI are differentially regulated during differentiation
yet WFDC2 is not induced by pro-inflammatory mediators. The majority of adenocarcinomas stain with WFDC2 whilst a
significant minority of squamous, small cell and large cell carcinomas exhibit focal staining. There is no clear association with
tumour grade.
Conclusion: We believe that these studies support the hypothesis that WFDC2 may be a component of the innate immune
defences of the lung, nasal and oral cavities and suggest that WFDC2 functions in concert with related WAP domain containing
proteins in epithelial host defence. We also suggest that WFDC2 re-expression in lung carcinomas may prove to be associated
with tumour type and should be studied in further detail.
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Background
The WAP 4-disulphide core domain 2 (WFDC2) gene
product, also known as human epididymis 4 (HE4), was
originally identified as a transcript exclusively expressed
in the epididymis and was proposed as a specific marker
for this tissue [1]. WFDC2 is a member of the Whey Acidic
Protein (WAP) domain family of proteins. The WAP
domain is a conserved motif of approximately 50 amino
acids, which contains eight cysteines found in a character-
istic 4-disulphide core arrangement [2]. WAP domain pro-
teins are usually small secretory proteins, which display a
variety of functions [2,3]. Two of the best-studied mem-
bers of this gene family are the antiproteinases, Secretory
Leukocyte Protease Inhibitor (SLPI) and elafin. SLPI con-
tains two WAP domains while elafin contains one. SLPI
and elafin, protect against proteolytic enzymes released by
inflammatory cells [3]. The major physiological function
of SLPI and elafin is considered to be the inhibition of
neutrophil elastase (NE), but they are also potent inhibi-
tors of a variety of other proteinases [3]. Beside these
shared antiproteinase activities, SLPI and elafin exhibit a
range of other host defence functions [4]. For example,
SLPI and elafin have antibacterial activities and both bind
to bacterial lipopolysaccharide (LPS) [4-8]. SLPI has also
been shown to block the in vitro replication of viruses [9]
and to promote cutaneous wound healing in mice [10].
Furthermore, SLPI and elafin may have anti-inflammatory
activities as SLPI inhibits monocyte/macrophage pro-
inflammatory functions [11] and we have shown that
elafin blocks inflammatory responses in the lungs of LPS
treated mice [12]. Both SLPI and elafin therefore play a
significant role in host defence.
On the basis of the similarity of WFDC2 to SLPI and elafin
it was suggested that the protein may function as an anti-
proteinase within the male reproductive tract and may be
important in the process of sperm maturation [1]
although this function has never been proven. Indeed,
although the function of WFDC2 remains unresolved a
number of studies have reported that WFDC2 RNA is
over-expressed in ovarian tumours [13-16] and in sub-
groups of lung adenocarcinomas [17,18]. Recent studies
have also shown that WFDC2 protein is overexpressed in
some types of ovarian cancer, principally serous and
endometrioid tumours [16,19,20]. Such studies suggest
that WFDC2 may play an undefined role in carcinogenesis
and/or tumour progression. These studies also propose
that WFDC2 may have some utility as a histological
marker for ovarian cancer [16,19,20] and serum WFDC2
levels have been suggested to be a sensitive marker for
ovarian cancer [19].
We recently showed that WFDC2 is expressed in a number
of normal human tissues outside of the male reproductive
system, including the trachea, lung and nasal epithelium
and is also found in a subset of pulmonary epithelial-
derived tumour cell lines [21]. The co-expression of
WFDC2, SLPI and elafin in these tissues further suggests
that WFDC2 may play an as yet undefined role in the host
defence of the respiratory tract [21]. Disregulation of the
proteinase/antiproteinase balance is thought to play a role
in the development of many respiratory conditions
including, chronic obstructive pulmonary disease
(COPD) and cystic fibrosis (CF) [22]. As well as being
altered in patients with a variety of lung diseases [23,24]
it has been shown that both SLPI and elafin are regulated
by proinflammatory stimuli [25,26]. Such observations
suggest that WFDC2 may function to protect the lung in
similar conditions and that expression of WFDC2 may be
altered in pulmonary disease.
In this paper we have studied the distribution of WFDC2
throughout the normal respiratory tract and in oral and
nasal tissues as well as in the lungs of patients with CF.
Additionally we have studied the expression of WFDC2 in
primary lung-derived epithelial cells. We believe that
these results further support the hypothesis that WFDC2
may be involved in host defence and suggest that altered
expression of this gene may influence host defence capa-
bilities of the lung and may prolong pulmonary inflam-
mation. We have also studied expression of WFDC2 in a
range of pulmonary carcinomas and show that expression
of the protein is associated with the majority of adenocar-
cinomas as well as in a significant minority of other lung
tumour types.
Methods
Immunohistochemistry
For nasal, oral and lung tissue, serial sections were cut
from formalin-fixed and paraffin-embedded tissue with
appropriate ethical approval as described [27]. For normal
tissues sections were taken so as to be as representative of
normal architecture as possible although as all tissues
were removed for medical reasons there was some evi-
dence of disease in some sections. Sections from the
major bronchi and peripheral lung were cut from 10 cases
of normal lung and similar samples were also obtained
from 10 patients with CF who were undergoing lung
transplantation. We also purchased lung cancer tissue
arrays from BioCat (Cat Number, US Biomax LC801
[28]), Superbiochips (Cat Number CCA-SBC [29]) and
AccuMax (Cat Number A206 [30]). These arrays con-
tained 150 lung cancer specimens of known diagnosis and
stage, 10 metastatic samples from matched primary
tumour cases, along with 15 samples of normal human
peripheral lung tissues. The cores on these samples were
1.5–2 mm in diameter. The specific diagnosis was con-
firmed by one of us (W.A.W.). The slides were treated with
2% hydrogen peroxide in methanol to quench endog-
enous peroxidase. The following antibodies (and dilu-Respiratory Research 2006, 7:61 http://respiratory-research.com/content/7/1/61
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tions) were used in this study. A monoclonal antibody
raised against human WFDC2 (clone 12H5) [18] (final
dilution 1:500), a monoclonal antibody to human SLPI
(clone 31, HBT, Holland, final dilution 1:250), a polyclo-
nal antibody to human mucin (Muc5AC, a gift from
David Thornton, University of Manchester, UK [31] final
dilution 1:250) and SPLUNC1 [32] (final dilution 1:500).
A standard antigen retrieval procedure was used for the
SLPI and Muc5AC antibodies. Sections were incubated
with 100% normal serum (horse for WFDC2 and SLPI
and goat for Muc5AC and SPLUNC1) at room tempera-
ture for 30 minutes and then at 4°C overnight with the
antibodies diluted as indicated above with normal serum.
Rabbit or mouse IgG (DAKO) were used as negative con-
trols on replicate slides. A Vectastain Elite ABC kit (Vector
Laboratories) containing an appropriate biotin-labelled
secondary antibody was used according to the manufac-
turer's instructions. Peroxidase enzymatic development
was performed using a Vector NovaRed substrate kit
resulting in red staining in positive cells. Sections were
counterstained with haematoxylin, dehydrated to xylene
and mounted in DPX. Staining of the lung cancer sections
was scored as negative, focal or positive.
Tissue culture
Human tracheobronchial epithelial (TBE) cell cultures
were prepared by methods described previously [33].
Human tracheas and bronchi were obtained from lungs
that were not deemed suitable for transplant through the
Life Alliance Organ Recovery Agency of the University of
Miami and approved by the local institutional review
board. The mucosa from the larger airways was dissected
and digested with protease, and released cells were col-
lected by centrifugation. Cells were plated on collagen-
coated culture dishes with bronchial epithelial growth
medium [33] and harvested with trypsin after reaching
confluence. These de-differentiated cells were plated onto
24-mm Transwell-clear culture inserts coated with human
placental collagen. The cultures were maintained in a
medium containing 50% DMEM and 50% LHC basal
medium (Biosource International, Camarillo, CA, USA)
supplemented with hormones and trace elements as
described [33]. Upon reaching confluence (after 3–7
days), the medium from the apical surface was removed,
leaving the top surface exposed to air (air-liquid interface
cultures, ALI). To study the effect of retinoic acid (RA) on
the expression of WAP protein genes normal [RA] (50
nm) was removed from the medium of fully differentiated
cells after 14 days in culture.
Type II alveolar epithelial cells were isolated as previously
described [34] from unused donor organ material sup-
plied by the UK Human Tissue Bank with appropriate eth-
ical approval. Cells were cultured in standard 12-well
tissue culture plates. To study the effects of pro-inflamma-
tory mediators on WAP protein expression in both pri-
mary cell types, cultures were stimulated with IL-1β,
TNFα, (both from R & D Systems, Inc, Minneapolis, MN,
USA) or E.coli LPS (Sigma, St Louis, MO, USA) for 24 or
48 hours prior to harvest. Stimulations for RNA analysis
were performed on at least 3 occasions.
RNA extraction and RT-PCR
Total RNA was isolated as previously described [35].
Reverse transcription was also performed as previously
described [36] in a total volume of 20 µl using an oligo-
dT primer and 1 µg of total RNA. PCR reactions were per-
formed using 1 µl of each reaction product and the follow-
ing primer pairs. WFDC2 F: 5' CGG CTT CAC CCT AGT
CTC AG 3'; WFDC2 R: 5' AAA GGG AGA AGC TGT GGT
CA 3'; Elafin F: 5' ACC TTC CTG ACA CCA TGA GG 3';
Elafin R: 5' GAT GAG AGA GGC AGC TCC AG 3'; SLPI F:
5' ATG AAG TCC AGC GGC CTC TT 3'; SLPI R: 5' CAT ATG
GCA GGA ACT AAT CT 3'; Muc5B F: 5' ACT CCT GTC AAG
TCC GCA TC 3'; Muc5B R: 5' ATC CAC GTG GGT GTA
GGT GT 3'; CCSP F: 5' GTC ACA CTG GCT CTC TGC TG
3'; CCSP R: 5 GAG CAG TTG GGG ATC TTC AG 3'. All
primer pairs were designed to cross introns. 27–35 cycles
of the following program (94°C for 1', 60°C for 2' and
72°C for 3') generated the appropriately sized products,
which were resolved on 2% TAE agarose gels, stained with
ethidium bromide and photographed. Representative
samples of each were directly cloned in TOPO pCRII (Inv-
itrogen) and sequenced.
Results
To study the localisation of human WFDC2 protein we
used a monoclonal antibody raised against recombinant
human WFDC2 [19]. This antibody has previously been
used for both immunohistochemical analysis of WFDC2
in ovarian cancers as well as in ELISAs [19,37,38]. The
antibody was also shown to specifically identify human
WFDC2 in western blots of in vitro translation reactions
(results not shown).
In the light of our previous observation that significant
expression of WFDC2 RNA was seen in tissue from the
nasal passages [21], we initially stained sections from the
maxillary sinus (antral) mucosa and nasal polyps. In these
sections there was significant staining in the ductular epi-
thelium of the minor glands, with less pronounced stain-
ing in the mucous cells of the glands themselves (Figure
1A, B). The surface epithelium of the nasal passages was
also weakly positive. We stained nasal polyps from >15
individuals all of which demonstrated WFDC2 in ductular
cells of the minor mucous glands (Figure 1C), although
the intensity of staining varied and some regions of indi-
vidual glands were found to be negative. The respiratory
epithelium overlying the polyps was found to stain in a
similar manner to the maxillary sinus. We then went on toRespiratory Research 2006, 7:61 http://respiratory-research.com/content/7/1/61
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examine pulmonary tissue and in sections from central
bronchi the most prominent staining was again seen in
sub-mucosal glands (Figure 1D, E) and was restricted to
what phenotypically appear to be serous cells within the
demilunes (Figure 1E). Cells within the surface bronchial
epithelium from both major and minor airways were also
stained (Figure 1D, F), although in the 10 samples studied
both the intensity of staining and the number of cells
stained varied (results not shown). In contrast to the pos-
itive staining seen in sections of the bronchi, none of the
>20 samples of peripheral lung studied revealed clear
WFDC2 staining in alveolar epithelium (Figure 1G).
In the light of our finding that WFDC2 staining was prom-
inent in the minor glands of the upper airways, and our
previous observation that WFDC2 was highly expressed in
salivary gland RNA, we extended our studies to look at
WFDC2 staining in both major and minor salivary glands.
For all of these samples we stained sections from at least 3
individual patients. The three major salivary glands
showed a striking distribution of WFDC2, predominantly
in the ductular epithelium of the glands. In the parotid
gland this intense staining of the excretory ducts was also
accompanied by some staining in a few of the serous cells
of the acini (Figure 1H). Similar staining in the excretory
ducts was seen in the sub-mandibular gland along with
staining in the striated and intercalated ducts, although in
this tissue staining was not seen in serous cells within the
acini themselves (Figure 1I). In the sublingual gland the
strong ductular staining was also accompanied by staining
within the serous demilunes of the predominantly muci-
nous acini, although the intensity of this staining was less
marked than in the ducts. (Figure 1J). In samples of the
posterior portion of tongue again the minor glands dem-
onstrated strong WFDC2 staining (Figure 1K) and minor
glands of the vallecular region of the tongue, associated
with tonsil, also stained with WFDC2 (Figure 1L). In both
of these glands the majority of the cells of the ducts
expressed the protein very intensely. Most of the tonsil tis-
sue, including tonsillar crypts or germinal centres, did not
stain (results not shown).
These results clearly show that WFDC2 is present in a vari-
ety of glands associated with the upper respiratory tract,
nasal passages and oral cavity and also suggest that the
protein is present in a subset of upper airway epithelial
cells. In addition, a significant site of WFDC2 protein
localisation appears to be ductular cells of the major sali-
vary glands. WFDC2 is not found at significant levels in
the peripheral lung.
To complement our studies of the distribution of WFDC2,
and to gain further insights into the cells that express the
protein, we carried out more immunohistochemical stud-
ies, using additional antibodies on serial sections of mul-
tiple tissues. In the submandibular gland it is clear that
expression of WFDC2 and the related 2-WAP domain con-
taining protein, SLPI are almost mutually exclusive. As
previously shown, (Figure 1I) WFDC2 was present in the
ducts of the gland whereas SLPI was found in both the
serous and (rarer) mucous cells of the gland (Figure 2A,
B). SLPI staining was absent from the ducts. Staining for
SPLUNC1 (a mucous cell marker [27]) was found to be
strongest in the mucous cells of the gland with weak stain-
ing in the ductular cells (Figure 2C). A similar distribution
pattern was seen in the submucosal glands of the bronchi-
olar epithelium where WFDC2 was found in the ductular
cells and a subset of cells in the serous demilunes of the
predominantly mucinous acini (Figure 2D). The majority
of mucous cells did not stain with WFDC2. In this tissue,
however, SLPI staining was found in some of the ductular
tissues that express WFDC2 as well as the mucous cells of
the gland (Figure 2E). SPLUNC1 was clearly localised in
the mucous cells of the gland (Figure 2F). These results
show that WFDC2 is distributed in a distinct subset of
cells within both major and minor salivary glands but it is
not completely co-expressed with the related protein SLPI.
Distribution of WFDC2 in the respiratory tract and salivary  glands Figure 1
Distribution of WFDC2 in the respiratory tract and 
salivary glands. Immunohistochemistry for WFDC2 was 
performed as described in materials and methods. Sections 
show staining in nasal antral mucosa (A, B), nasal polyps 
(C), airway sub-mucosal glands (D, E), epithelial cells of the 
airways (F) and negative staining in peripheral lung (G). 
Staining was also found in parotid (H), submandibular (I) and 
sub-lingual (J) glands and minor glands from the tongue (K) 
and tonsil (L). The original magnification of the images was 
×100 (A, B, C, D), ×200 (E, F, H, I, J) and ×400 (G, K, L).Respiratory Research 2006, 7:61 http://respiratory-research.com/content/7/1/61
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As chronic inflammation within the lung has been associ-
ated with alterations in the levels of SLPI and elafin [23-
25], we studied WFDC2 expression in chronically
inflamed lung using airway and peripheral lung sections
from 10 patients who had undergone transplantation for
CF. In sections of large airways from these samples there
was no clear alteration in either the site or level of staining
within the bronchiolar epithelial cells or the submucosal
glands (results not shown). However, the situation in the
smaller airways within the peripheral lung sections was
markedly different. WFDC2 staining in the abnormal
(hyperplastic) epithelium was found to be more generally
distributed in the epithelium (Figure 3, C, D, G) com-
pared to the situation seen in similar sized airways from
CF disease-free lung (Figure 1F and Figure 3A). In addi-
tion to the greatly increased staining seen within the epi-
thelium, the inflammatory mass within the airway lumen
was also found to stain strongly for WFDC2 (Figure 3C
and 3G). Sections stained with SLPI clearly did not display
the same increased expression as was seen with WFDC2.
In non-diseased small airways, SLPI was limited to cells
with the phenotypic characteristics of goblet cells (Figure
3B). In CF sections stained with the same antibody, SLPI
immuno-reactivity was markedly reduced compared to
normal lung (Figure 3E, H) and was not detectable in the
inflammatory exudates within the lumen of the small air-
ways (Figure 3H). In contrast staining of sections with the
goblet cell marker Muc5AC clearly showed that there was
a significant increase in the number of mucous secreting
cells in the CF airway (Figure 3F, I). The luminal content
of these small airways also stained strongly for Muc5AC
(Figure 3I). These results indicate that WFDC2 immuno-
reactivity is increased in the lungs of patients with CF and
furthermore suggest the protein is secreted into the lumi-
nal contents of the diseased lung. This suggests that
although expression of the WFDC2 gene may be mediated
by inflammatory signals this may be different to that pre-
viously described for the related proteins SLPI and elafin.
To directly address the question of potential regulation of
WFDC2 by inflammatory mediators we performed a series
of RT-PCR studies using primary human lung derived
cells. In our previous study we had shown that WFDC2
was expressed in a number of lung cancer cell lines, some
of which also expressed SLPI and elafin [21]. Given the
localisation of WFDC2 staining in cells of the bronchiolar
epithelium we initially chose to study primary cells from
this region. We confirmed that WFDC2 mRNA was readily
detectable in submandibular and parotid gland and in
NCI-H358 cells (results not shown). When RT-PCR reac-
tions were performed on bronchial epithelial cells directly
harvested from healthy donor lungs WFDC2 mRNA was
readily detected (Figure 4A, lane H). Reduced expression
of WFDC2 was seen as the cells underwent the process of
de-differentiation when plated in collagen-coated dishes
for 3 days, allowed to expand (P1), and plated again for a
second passage (P2). During this period of submerged
culture the cells lose features of differentiation, confirmed
WFDC2 is abnormally expressed in the Cystic Fibrosis lung Figure 3
WFDC2 is abnormally expressed in the Cystic Fibro-
sis lung. Sections of normal (A, B) and Cystic Fibrosis lung 
(C – I) were stained with WFDC2 (A, C, D, G), SLPI (B, E, 
H) and mucin 5AC (F, I) as described in materials and meth-
ods. The original magnification of the images was ×100 (A, B) 
and ×200 (C, D, E, F, G, H, I).
WFDC2 and SLPI do not co-localise in major and minor  glands Figure 2
WFDC2 and SLPI do not co-localise in major and 
minor glands. The expression of WFDC2 (A, D) was 
directly compared with that of the related 2-WAP domain 
containing protein SLPI (B, E) and the mucous cell marker 
SPLUNC1 (C, F) in multiple glandular tissues as described in 
the materials and methods. Sections shown are submandibu-
lar gland (A-C) and bronchial sub-mucosal glands (D-F). The 
original magnification of the images was ×200.Respiratory Research 2006, 7:61 http://respiratory-research.com/content/7/1/61
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by the complete loss of expression of the Clara cell secre-
tory protein (CCSP) gene, a marker of differentiated bron-
chiolar cells (Figure 4A). When the cells were placed at an
air-liquid interface they re-differentiated as evidenced by
the visual appearance of cilia (results not shown) and re-
expression of CCSP. At this stage, expression of WFDC2
was increased to levels similar to those observed in
directly harvested cells (Figure 4A, lane d14). Similar
results were found in two other sets of cells (results not
shown).
To further investigate the role of differentiation of the ALI
cells in influencing the expression of WFDC2 we modu-
lated the differentiation status of the cells by removing
retinoic acid from the culture medium. 50 nm RA is nor-
mally present in the culture medium of these cells and has
been shown to be required for full differentiation of the
cultures [39]. Removal of RA from these cultures led to a
progressive loss of WFDC2 expression such that following
18 days of RA withdrawal, expression was essentially lost
(Figure 4B). Levels of expression of SLPI in the same sam-
ples were clearly not influenced by the removal of RA (Fig-
ure 4B) whereas, in marked contrast, expression of elafin
almost completely mirrored that of WFDC2 with the RA
depleted cells having significantly more expression of the
elafin gene. The requirement for RA to maintain the
mucous secretory phenotype of the cells was shown by the
loss of expression of Muc5AC that paralleled the loss of
WFDC2 (Figure 4B). Again we found similar results in two
further sets of experiments with cells from different
donors (results not shown).
We also examined the role of pro-inflammatory stimuli
on the expression of WFDC2 in the ALI cells. For these
studies differentiated cells were exposed to levels of IL-Iβ,
TNFα and E. coli LPS known to induce expression of a vari-
ety of responsive genes. Neither TNFα nor LPS was found
to induce expression of WFDC2 under any conditions
(results not shown). Similar negative findings were found
with IL-1β (Fig 4C) but this cytokine does upregulate
elafin gene expression. The expression of SLPI mRNA was
not significantly altered by any of these treatments (results
not shown). These results appear to suggest that although
expression of WFDC2 in ALI TBE cells is influenced by dif-
ferentiation status, classical pro-inflammatory mediators
do not appear to regulate the gene.
We have previously shown that SLPI and elafin are consti-
tutively expressed in primary type II alveolar epithelial cell
cultures and that elafin expression is induced by IL-1β in
these cells [26], thus we performed similar induction
studies with WFDC2. WFDC2 gene expression was readily
detected in control Type II cells (Figure 4D). Stimulation
with the same pro-inflammatory mediators as was used
for the ALI cells suggested that WFDC2 was slightly
induced by IL-1β, but was not responsive to either TNFα
or LPS (Figure 4D). Again, and consistent with our previ-
ous studies [26], elafin expression was induced by IL-1β
but was not altered by either TNFα or LPS treatment in the
Type II cells. SLPI was not altered by any of these stimula-
tions. We have also found a similar lack of induction of
WFDC2 gene expression in lung cancer cell lines treated
with pro-inflammatory mediators (results not shown).
These results suggest that WFDC2 expression is not
responsive to pro-inflammatory mediators in primary
human lung cells and that the increased staining seen in
the CF lungs may be due to a phenotypic alteration of the
cell population rather than a direct transcriptional effect
on the WFDC2 gene.
In light of the multiple reports of disregulated WFDC2
expression in ovarian cancers [13-16] and the smaller
number of reports that the gene may also be differentially
expressed in sub-groups of pulmonary cancers [17,18] we
stained sections of a variety of lung carcinomas with the
WFDC2 antibody. To do this we used commercial tissue
arrays that contained 150 individual cases from a range of
different lung cancers. Representative results of this study
are shown in Figure 5 and the data is summarised in Table
1. For representation of the data, each section was scored
as being either negative, exhibiting focal positivity or
being positive throughout the tumour. In focal positive
cases the number and intensity of cells staining varied
widely as did the intensity of staining in the positive cases.
Due to the subjective nature of this assessment we have
not attempted to sub-divide either of these two groups. It
is clear from this data that both adenocarcinomas (Figure
5A–C) and bronchioloalveolar carcinomas (BAC, Figure
5D) exhibit the greatest percentage of positive staining
tumours (>80%). In the majority of these strong, positive
staining was identified throughout the tumour (Figure 5C
and 5D), although focal positive staining ranging from a
few cells within the tumour (Figure 5A) to focal staining
of all of the abnormal ductular tissue (Figure 5B) was also
seen. 12 of 63 cases of adenocarcinomas/BACs were neg-
ative. Focal staining was seen in 18 of 60 cases of squa-
mous carcinoma (Figure 5E), the majority of these
tumours were negative (Figure 5F). Focal staining was also
seen in a single case of adenoid cystic carcinoma (Figure
5G) whilst 11 of 14 cases of small cell carcinoma (Figure
5H) and a single case of mesothelioma were negative (Fig-
ure 5I). The majority of cases of large cell carcinoma (8 of
11) were negative with the remainder exhibiting weak
focal positive staining (results not shown). These results
suggest that WFDC2 staining is predominantly associated
with adenocarcinomas although a percentage of squa-
mous, small cell and large cell carcinomas also exhibit
focal positive staining.Respiratory Research 2006, 7:61 http://respiratory-research.com/content/7/1/61
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Discussion
We previously characterised the WFDC2 gene as part of an
analysis of uncharacterised WFDC genes expressed in the
airways [21]. Due to the similarities between WFDC2 and
other WAP family members it has been suggested that the
protein might function as an antiproteinase [1], although
this function is still unproven. The WFDC2 gene was ini-
tially suggested to encode an epididymal specific protein
[1], however, following the identification of a lung
derived EST we were able to show that the WFDC2 gene is
expressed in a range of tissues including the lung and sal-
ivary glands [21]. Other studies have identified WFDC2
over expression in ovarian and other cancers and have
focussed on its potential use as a cancer marker [13-
20,37,38]. The distribution and function of WFDC2 in
normal tissues remains largely unresolved and thus we
have extended our previous observations to study the
localisation of WFDC2 in the oro- and nasopharynx and
respiratory tract in an effort to gain a greater understand-
ing of the function of the protein.
Our results clearly show that WFDC2 protein is readily
detectable in multiple tissues from the oral cavity,
nasopharynx and respiratory tract. These results are con-
sistent with our previous studies of the gene [21]. Within
these tissues the protein is most readily detected in the
excretory ducts of both the major and minor glands as
well as being expressed in a sub-population of airway epi-
thelial cells. The expression of WFDC2 at these sites sug-
gests that it may, like the related family members SLPI and
elafin, be released into the secretions of the glands and the
epithelium. In support of this suggestion WFDC2 has
recently been identified as a component of bronchoalveo-
lar lavage [40]. In the absence of significant WFDC2 pro-
tein in the secretory cells of the respiratory epithelium our
results suggest that the protein enters the airway surface
lining fluid via secretion from the sub-mucosal glands. We
also directly compared localisation of WFDC2 with SLPI,
a 2-WAP domain containing antiproteinase family mem-
ber. SLPI is known to play a role in host defence in these
regions and has previously been shown to be highly
expressed in the submucosal glands [41]. Our results
showed that although both proteins are present within
the same tissues the precise cells in which they are found
is not completely identical, indeed they are found in an
almost mutually exclusive expression pattern in some tis-
sues. We believe this observation suggests that the two
proteins are under different regulatory control; this may
further imply the functions of the proteins are quite dis-
tinct. As outlined in the introduction, an antiproteinase
function for WFDC2 has been suggested but not demon-
strated. The physical spacing of two of the conserved
cysteine residues in the WAP domains of WFDC2 may, in
fact, not allow sufficient space for the generation of an
active antiproteinase site in the protein [2,3]. This would,
however, not exclude a host defence role for WFDC2, as
the host defence functions of other WAP domain contain-
ing proteins do not require an active antiproteinase
domain [2-4].
A variation in intensity of staining was seen within sam-
ples and between samples suggesting WFDC2 may be
locally produced in response to stimulation. We were una-
ble to show induction of WFDC2 gene expression in ALI
TBE cells but it appeared to be induced by IL-1β in pri-
mary type II cells. This suggests that expression of the
WFDC2 gene is differentially regulated in different cell
types although these finding need to be confirmed with a
greater range of treatments and doses, perhaps using more
WFDC2 is expressed in primary tracheal cells, differentiated  tracheobronchial epithelial cells and alveolar Type II epithelial  cells Figure 4
WFDC2 is expressed in primary tracheal cells, differ-
entiated tracheobronchial epithelial cells and alveo-
lar Type II epithelial cells. A. Expression of WFDC2 was 
studied by PCR using freshly harvested human tracheal cells 
(H) and samples taken from the cultures at two stages (P1, 
P2) as the cells were established at an air liquid interface 
(ALI). Expression of the non-ciliated tracheal cell marker 
CCSP was also monitored in the same samples. B. Expres-
sion of WFDC2 was studied by PCR in samples of primary 
tracheobronchial epithelial cells during retinoic acid deple-
tion and the subsequent loss of the differentiated phenotype. 
The normal concentration of retinoic acid (50 nm RA) was 
removed (-) over the indicated period of days. RA with-
drawal began at day 14. Expression of the related WAP 
domain containing proteins SLPI and elafin and the non-cili-
ated and mucous markers CCSP and Muc5B were also stud-
ied in the same samples. C. Expression of WFDC2 and elafin 
was studied by PCR in samples of differentiated primary tra-
cheobronchial epithelial cells following treatment with IL-1β 
for 24 and 48 hours D. Expression of WFDC2, SLPI and 
elafin was studied by PCR in samples of primary alveolar epi-
thelial pneumocytes (Type II cells) following treatment for 24 
hours with LPS (2), TNFα (3) or IL-1β (4).Respiratory Research 2006, 7:61 http://respiratory-research.com/content/7/1/61
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sensitive techniques. In comparison, expression of elafin
is only seen in type II epithelial cells after stimulation with
IL-1β [26] whilst SLPI is constitutively expressed and not
affected by cytokines. The fact that WFDC2, SLPI and
elafin are differentially regulated by inflammatory stimuli
suggests subtle differences in either their function or sites
of action. The lack of induction by such stimuli does not
exclude a host defence function for WFDC2 as not all host
defence proteins are induced in this manner. For example
SLPI is known to have potent anti-microbial activities,
both anti-viral and anti-bacterial, but gene expression is
not upregulated in our LPS stimulation studies. This
observation is consistent with other reports [42,43]. Fur-
ther studies of both gene and protein expression follow-
ing treatment with a range of microbial products should
clarify the function of WFDC2.
When we examined WFDC2 protein expression in the
chronically inflamed lung from patients with CF we found
no marked difference in the upper airways compared to
normal samples but dramatically increased expression in
the peripheral lung. In direct contrast, the expression of
SLPI was dramatically reduced in the CF tissues; indeed it
was very difficult to find any positive staining in the
periphery of these damaged lungs. The tissue structure was
completely altered in the peripheral lung with hyperplasia
and many airways being obstructed with inflammatory
exudates. Our PCR studies indicate that the increased
expression of WFDC2 may not be a result of the action of
inflammatory mediators but may be due to an increase in
the number of cells secreting WFDC2 or a change in cell
phenotype. Similarly, the loss of SLPI staining in the CF
lung may also be due to phenotypic alteration in the epi-
thelium. This suggestion is supported by the difference in
expression of the WFDC2, SLPI and elafin genes during
the de-differentiation/re-differentiation of the TBE cells.
The alteration in expression of WFDC2 and SLPI proteins
in the CF tissue is not likely to be the direct result of the
CF mutation as it has recently been shown that TBE cells
from normal and CF donors have remarkably similar gene
expression signatures [44]. Further studies are required to
elucidate the mechanism of this difference in CF. Poten-
tially; levels of WFDC2 in CF lung secretions may influ-
ence the development of lung disease in this condition.
A number of different expression studies have clearly
identified that WFDC2 is disregulated at the RNA level in
ovarian cancers [13-16] and a recent study has suggested
that measuring levels of WFDC2 in the serum of patients
with ovarian cancer may be useful in monitoring disease
progression [19]. Furthermore immunohistochemical
studies, coupled with molecular classification array exper-
iments, have shown that re-expression of WFDC2 may be
associated with specific types of ovarian cancers [16,20].
The association of WFDC2 re-expression with other types
of cancers has not been addressed in any great detail,
although it has been shown in molecular classification
studies that WFDC2 expression is associated with differ-
ent subtypes of adenocarcinomas and some other lung
cancer types [17,18]. Our present results clearly show that
WFDC2 protein is readily detectable in a range of lung
tumour types. Principle among these are adenocarcino-
mas, where the majority of cases were found to be positive
for the protein. This study also clearly shows that WFDC2
expression is not purely associated with this tumour type
as a significant percentage (20–30%) of other tumour
types, for example squamous, small and large cell carcino-
mas, also exhibited focal positive staining for the protein.
Although we saw clear expression of WFDC2 in the major-
ity of cases of adenocarcinomas, there were also a number
of cases (21%) that were negative. We were unable to
make a clear association between the type of staining pat-
tern and tumour grade in the group of samples that we
have examined thus far, but it is clear that they must
express a different subset of secreted proteins. Such differ-
ential expression of putative marker genes has been
shown to yield distinct "molecular signatures" in lung car-
cinomas [17], which may be useful in the development of
specific diagnostic and prognostic markers. Indeed two
studies have shown that pulmonary adenocarcinomas can
Distribution of WFDC2 in Pulmonary Neoplasms Figure 5
Distribution of WFDC2 in Pulmonary Neoplasms. 
Immunohistochemistry for WFDC2 was performed on three 
commercial lung cancer tissue arrays as described in materi-
als and methods. Representative samples were chosen for 
imaging. Examples of focal (A, B) and positive staining (C) in 
adenocarcinomas, positive staining in a BAC (D) and focal 
staining in a case of squamous carcinoma (E) are shown as 
well as a negative case of squamous carcinoma (F), focal 
staining in a case of adenoid cystic carcinoma (G) and a neg-
ative case of squamous carcinoma (H) and a mesothelioma 
(I). The original magnification of the images was 200X.Respiratory Research 2006, 7:61 http://respiratory-research.com/content/7/1/61
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be classified into different molecular phenotypes where
classification is associated with prognosis [17,18]. In
these studies low expression of WFDC2, as judged by gene
chip analysis, was associated with poor outcome [17,18].
One of these studies also showed that some groups of
non-adenocarcinoma lung tumours express increased
WFDC2 RNA levels as measured by chip analysis [17]. It
is tempting to speculate that the immunohistochemical
study that we report here may perhaps reflect the different
sub-classifications of lung tumours identified in these
expression array papers. Such a hypothesis would require
us to extend this analysis into a significantly larger series
of cases with better survival data and case histories. The
reason for the increased expression of WFDC2 in some of
the other pulmonary malignancies is also not clear and
will require further studies.
Conclusion
We have been able to show for the first time the precise
expression pattern of WFDC2 in the respiratory tract. The
protein, though found in a subset of epithelial cells and
present in the ASL fluid is predominantly present in the
mucous cells of the sub-mucosal glands of the upper air-
ways as well as in minor glands in the nose, sinuses, pos-
terior tongue and tonsil and the ducts of the major
salivary glands. These locations are all sites of production
of host defence proteins and the presence of protein in the
glandular and epithelial secretions supports the sugges-
tion that WFDC2 is involved in host defence. We have
also shown that WFDC2 is expressed in the majority of
cases of adenocarcinoma of the lung as well as being
found in a significant number of squamous, small cell and
large cell carcinomas of the lung suggesting it may have
some diagnostic and/or prognostic value. However, fur-
ther studies are needed to determine the precise function
and regulation of WFDC2 expression.
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